Trials / Conditions / Influenza A Virus Infection

Influenza A Virus Infection

13 registered clinical trials studyying Influenza A Virus Infection.

Status	Trial	Sponsor	Phase
Completed	The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac NCT03651544	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	Phase 1
Completed	Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatmen NCT02572817	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
Completed	Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents NCT02250274	Marshfield Clinic Research Foundation	Phase 4
Completed	Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening NCT01546506	Hospices Civils de Lyon	Phase 2
Completed	Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China NCT01459081	Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 3
Completed	Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment NCT01146535	Ainos, Inc. (f/k/a Amarillo Biosciences Inc.	Phase 2
Completed	Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Infl NCT01175122	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Blood and Plasma Collection For Use in Future Clinical Trials NCT01136057	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Antiviral Therapy for Influenza A H1N1 NCT00985582	South East Asia Infectious Disease Clinical Research Network	—
Completed	A Pilot Study for Collection of Anti-Influenza A Immune Plasma NCT00984451	National Institute of Allergy and Infectious Diseases (NIAID)	—
Withdrawn	Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit NCT00844155	University of Manitoba	N/A
Completed	Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children NCT00491985	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy NCT00457509	Sanofi Pasteur, a Sanofi Company	Phase 1